Continuing Education Activity

Actinic purpura, also termed senile or solar purpura, represents a benign yet visually striking dermatologic condition that occurs predominantly in older adults with significant cumulative ultraviolet exposure. The condition manifests as recurrent, sharply demarcated purpuric macules or patches on sun-exposed areas, most notably the dorsal hands and extensor forearms. Chronic photoaging leads to dermal atrophy, collagen degradation, and loss of vascular support, predisposing fragile capillaries to rupture even after minimal trauma. Lesions are noninflammatory, painless, and typically resolve within 1 week to 3 weeks without scarring or pigmentary change. Histopathologic findings reveal epidermal thinning, solar elastosis, and erythrocyte extravasation with minimal inflammation. Diagnosis is primarily clinical, with management centered on patient education, photoprotection, and topical agents such as retinoids to enhance dermal resilience. Although benign, actinic purpura underscores the long-term effects of photoaging and highlights the need for proactive sun protection and regular skin assessment in aging populations.

Through this continuing education activity, the participant comprehensively understands actinic purpura, including its pathophysiology, clinical features, and evidence-based management strategies. The course emphasizes the critical role of interprofessional collaboration in optimizing patient outcomes. Dermatologists, primary care clinicians, nurses, and pharmacists contribute unique expertise that enhances patient education, promotes consistent photoprotection practices, and ensures safe topical or pharmacologic therapies. Coordinated communication among team members supports early recognition of atypical presentations, prevents unnecessary diagnostic testing, and strengthens adherence to preventive measures. By integrating clinical insight with coordinated care, the interprofessional team improves patient quality of life, fosters self-management confidence, and advances dermatologic care standards for individuals affected by actinic purpura.

Objectives:

• Apply evidence-based strategies to prevent, diagnose, and manage actinic purpura using dermatologic guidelines emphasizing skin barrier restoration and ultraviolet protection.
• Differentiate actinic purpura from conditions such as thrombocytopenic purpura, vasculitis, or medication-induced bruising through comprehensive clinical assessment.
• Implement preventive measures, including daily broad-spectrum sunscreen use, protective clothing, and avoidance of topical or systemic corticosteroids that worsen dermal fragility.
• Collaborate with the interprofessional team to educate, treat, and monitor patients with actinic purpura to improve patient outcomes.

Introduction

Actinic purpura is a common benign disorder of dermal connective tissues due to skin damage from chronic sun exposure. This condition was initially described by Bateman in 1818 and is also known as Bateman senile purpura or Bateman disease. Usually affecting older adults, this condition is characterized by dark purple blotches on photo-exposed areas, especially the back of the hands and the extensor surfaces of the forearm. These lesions normally fade for up to 3 weeks.[1][2] Some authors have used the term solar purpura as a synonym for actinic purpura, but reserving it for purpuric lesions that occur acutely after sun exposure is preferable.[3] See Image. Actinic Purpura.

Etiology

Actinic purpura results from the fragility of the skin, which occurs due to long-term sun exposure, leading to ultraviolet-induced dermal atrophy. The dermal connective tissue cannot support microvasculature adequately, leading to extravasation of the blood into the dermis after a minor trauma, which is often neglected in medical history. This is one of the signs of dermatoporosis, which indicates skin fragility, skin atrophy, and stellate pseudo scars.[4][5][6]

Epidemiology

Actinic purpura is common among older adults, especially those with fair skin who are more sensitive to sun exposure. The prevalence increases with age and years of exposure to ultraviolet light. There is an estimation that this condition is present in about 12% of individuals older than 50, and in 30% of those aged 75 and older. Actinic purpura usually affects both sexes equally.[7]

Pathophysiology

Actinic purpura results from the extravasation of blood into the dermis. This phenomenon is due to the skin atrophy and fragility of the blood vessels in older adults, which is exacerbated by chronic sun exposure. The lesions of actinic purpura are commonly located on sun-exposed areas, like the arms, face, and neck. Skin atrophy in dermatoporosis is due to an alteration of collagen. These collagen changes may correspond to bone density changes similar to osteoporosis; it is postulated that bone collagen also changes along with skin collagen, which leads to an alteration in bone density. The pronounced skin atrophy caused by the photo-aging and ultraviolet radiation exposure makes the dermal vascular network very sensitive to the slightest trauma or shearing force.[8]

The formation of purple patches and macules of this condition develops due to the passage of red blood cells into the dermis, resulting in hemosiderin deposition in the interstitial space. There is no infiltration of the vessels and usually no inflammatory reaction of the dermal tissue. The absence of phagocytosis results in delayed resorption of extravasated blood. This fact results in purple patches and macules of the ecchymotic aspect.[3]

Histopathology

Histopathology of skin shows thinning of the epidermis with many abnormal keratinocytes in a disorderly pattern. The dermis shows extravasation of red blood cells and hemosiderin deposition with no inflammatory cells. Histology of the surrounding skin with solar elastosis appeared as blue homogenized elastotic material, which is present at the base of the epidermis. The amount of collagen in the affected area is markedly decreased.[8][9]

History and Physical

Actinic purpura presents as patches and macules with irregular edges on the forearm and back of the hands. However, they can affect other areas, such as the legs, neck, and face. The lesions may appear as dark purple macules and extensive ecchymosis, with average sizes ranging from 1 cm to 4 cm in diameter. These macules are asymptomatic and are not associated with pruritus or tenderness. The surrounding skin generally exhibits altered qualities, appearing thin, pigmented, and inelastic. Besides the typical presentation of actinic purpura, there may be evidence of other photo-aging lesions such as wrinkling, lentigines, sallow yellow skin hue, and actinic keratosis and stellate pseudo scars.[10]

The purpuric lesions persist for about 1 to 3 weeks before resolving spontaneously. However, they do not undergo the phases of inflammation. A residual deposit of hemosiderin in the dermis may leave a brown pigmentation. Actinic purpura can continue to occur because of the already established cutaneous and vascular fragility. The ecchymotic lesions can cause a significant aesthetic problem and have a psychological impact; however, there is no risk of serious complications.[3]

Evaluation

The diagnosis of actinic purpura is primarily clinical, based on a careful patient history and physical examination, including assessment of lesion distribution on chronically sun-exposed areas, skin quality, and the absence of systemic symptoms. Lesions are painless, noninflammatory, and resolve without scarring within 1 week to 3 weeks. Histopathologic evaluation is rarely required but, when performed, demonstrates a thinned epidermis over an atrophic dermis with reduced collagen and abnormal elastic fibers. Dermal vessels maintain normal tensile structure, but red blood cell extravasation and hemosiderin deposition are highlighted by Perl staining. In approximately 10% of cases, neutrophilic infiltration may be observed, which can mimic neutrophilic dermatoses or leukocytoclastic vasculitis, potentially leading to misdiagnosis.[11]

Laboratory testing is generally unnecessary unless atypical features or systemic involvement are suspected. Coagulation studies, complete blood counts, and platelet assessments are typically normal and reserved for patients with unusual bleeding, rapid lesion progression, or concomitant systemic symptoms. Imaging studies are not indicated for routine evaluation, as actinic purpura is confined to the dermis and does not involve deeper tissues.

Current national and international dermatology guidelines, including those from the American Academy of Dermatology and European Dermatology Forum, recommend a clinical diagnosis without routine laboratory or radiographic evaluation, reserving additional testing for atypical presentations or when alternative diagnoses, such as vasculitis, coagulopathy, or drug-induced purpura, are being considered.[11] Management decisions are guided by the clinical evaluation, emphasizing photoprotection, trauma avoidance, and, when appropriate, topical agents to improve dermal thickness. Clear documentation of lesion appearance, distribution, and patient history supports differentiation from other purpuric disorders and ensures targeted patient education.

Treatment / Management

Actinic purpura is a benign condition that does not require specific treatment, particularly since other lesions continue to appear throughout life. The best preventive treatment involves protection from excessive sun exposure by applying sunscreen and wearing long-sleeved shirts. One should apply sunscreens with a high protection index (sun protection factor greater than 50) daily to provide sufficient protection against ultraviolet A and ultraviolet B rays. The sunscreen should be liberally applied to all sun-exposed areas regularly.[12][13]

The therapeutic possibilities available for the actinic purpura lesions already formed are restricted. Tretinoin or retinoic acid (0.1%) is a vitamin A derivative, which could theoretically reverse severe skin damage induced by ultraviolet light. Indeed, topical tretinoin is known for its role in regenerating dermal collagen and reducing the quality of abnormal elastin damaged by solar exposure. However, some authors demonstrate that the developed plaques of actinic purpura do not improve under local treatment with tretinoin.[1][3] 

In 2002, actinic purpura was successfully treated in 1 patient with tissue-engineered skin; however, no similar cases have been reported. More recently, it has been demonstrated that the human epidermal growth factor may be a viable treatment for actinic purpura. This has been shown to increase the average skin thickness and reduce the number of purpuric lesions when applied twice daily for 6 weeks. A citrus bioflavonoid blend has been tested for the treatment of actinic purpura. After 6 weeks, the treated group showed a 50% decrease in purpuric plaques with no reported side effects.

Laser therapy is not indicated for actinic purpura, even though it is commonly used to treat other signs of skin aging.  Moisturizing creams may be useful to treat associated skin xerosis.[10] Results from recent studies have revealed that a new intense pulsed light protocol is safe and effective in improving the clinical appearance of actinic purpura and preventing future lesions by improving the skin's structure by increasing epidermal thickness and improving collagen and elastic fiber morphology. The treatment was well-tolerated, adverse effects were minimal, and there was high patient satisfaction.[14][15][16]

Differential Diagnosis

The differential diagnosis of actinic purpura includes the following: 

• Steroid-induced purpura
• Physical trauma
• Use of anticoagulants
• Scurvy (vitamin C deficiency)
• Vitamin K deficiency
• Psychogenic purpura
• Palpable purpura (hemorrhage and inflammation)
• Primary systemic amyloidosis [17]

Prognosis

The disease has a good prognosis and a benign course. The lesions typically continue to occur throughout life, but they usually resolve in 1 week to 3 weeks. They may leave postinflammatory hyperpigmentation or sometimes scarring, but they are not associated with any other major complications.

Complications

Actinic purpura is a benign condition and usually resolves in 1 week to 3 weeks with residual pigmentation or sometimes scarring. These lesions can trigger the patient’s emotional distress due to cosmetic disfigurement.[3]

Deterrence and Patient Education

Deterrence and patient education for actinic purpura focus on minimizing further photodamage and preventing lesion recurrence through lifestyle modification and skin barrier support. Patients should be counseled on consistently using broad-spectrum sunscreens and protective clothing and avoiding peak ultraviolet exposure. Education should emphasize the role of cumulative sun damage and mechanical trauma in lesion formation. Gentle skin care routines, including emollients and avoiding irritants or anticoagulant topical products, help reduce vessel fragility. Clinicians should reinforce that actinic purpura is benign yet indicative of photoaged skin, highlighting the importance of ongoing photoprotection and proactive management of cutaneous aging.

Pearls and Other Issues

Actinic purpura is a common, benign disease of older adults with fair skin types. The disorder appears to be caused by dermal and vascular fragility induced by chronic sun exposure. This condition does not predispose to serious complications, and the risk of bleeding is minimal. However, it can cause significant aesthetic and cosmetic damage and can induce a significant psychological impact. Treatment is limited, mainly relying on creams based on vitamin A derivatives and moisturizers. Photoprotection remains the best option, and it is based on wearing physical protective clothing, regularly applying sunscreen, and using behavioral therapies to avoid excessive sun exposure and trauma.[18]

Enhancing Healthcare Team Outcomes

An interprofessional approach is essential in managing actinic purpura, particularly given its high prevalence among older adults and the fragility of chronically sun-damaged skin. Although actinic purpura is benign, minor trauma can easily lead to purpuric lesions, highlighting the need for coordinated patient education and preventive care. Primary care clinicians collaborate to assess skin integrity, identify patients at higher risk for complications, and provide individualized counseling on photoprotection, trauma avoidance, and skin hydration. Pharmacists support the team by reviewing medications that may increase bleeding risk and advising on topical therapies, such as retinoids or dermal repair agents, to improve skin resilience.

Effective interprofessional communication ensures that all team members are informed of the patient’s condition, progress, and any changes in risk status. Care coordination includes reinforcing sun-protective behaviors, monitoring for potential coexisting conditions such as actinic keratosis, and determining when biopsy or specialist referral is warranted.[12][18] Ethical considerations, including patient autonomy, informed consent, and culturally sensitive sun exposure counseling, are integral to maintaining trust and adherence. By leveraging the unique expertise of each discipline and promoting clear, ongoing communication, the healthcare team enhances patient-centered care, improves outcomes, supports patient safety, and strengthens overall team performance in the management of actinic purpura.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Ceilley RI. Treatment of Actinic Purpura. J Clin Aesthet Dermatol. 2017 Jun;10(6):44-50. [PMC free article: PMC5605207] [PubMed: 28979656]

2.

Gerber PA, Buhren BA, Schrumpf H, Hevezi P, Bölke E, Sohn D, Jänicke RU, Belum VR, Robert C, Lacouture ME, Homey B. Mechanisms of skin aging induced by EGFR inhibitors. Support Care Cancer. 2016 Oct;24(10):4241-8. [PMC free article: PMC5611667] [PubMed: 27165055]

3.

Syed HA, Masood S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 7, 2025. Actinic Purpura. [PubMed: 28846319]

4.

Bortolozo F, Rinaldi M, Souza P, Schütz Paschoal Â, Lemperle G. Dermatoporosis in Upper Limbs Treated With Polymethylmethacrylate Microspheres Using the BioSculpt® Technique. Cureus. 2023 Aug;15(8):e43789. [PMC free article: PMC10440045] [PubMed: 37605716]

5.

Brouwer MW, Kemperman PM. [A woman with red-purple blotches]. Ned Tijdschr Geneeskd. 2013;156(0):A3305. [PubMed: 24326109]

6.

Peres GRP, Bandeira da Silva CV, Strazzieri-Pulido KC, de Gouveia Santos VLC. Skin tears in older adult residents of long-term care facilities: prevalence and associated factors. J Wound Care. 2022 Jun 02;31(6):468-478. [PubMed: 35678790]

7.

Luger A. [The skin in the elderly]. Z Gerontol. 1988 Sep-Oct;21(5):264-6. [PubMed: 3070998]

8.

Rayner RL, Carville KJ, Leslie GD, Dhaliwal SS. Clinical purpura and elastosis and their correlation with skin tears in an aged population. Arch Dermatol Res. 2019 Apr;311(3):231-247. [PubMed: 30783769]

9.

Borroni RG, Grassi S, Concardi M, Agozzino M, Caspani C, Giordano C, Vignini M, Arbustini E. Involvement of dermal microvascular basement membrane in senile purpura: quantitative immunohistochemical study. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e63-e65. [PubMed: 26404419]

10.

Durso TA, Miletta NR, Ortiz A, Avram M. Laser Therapy for Actinic Purpura. Dermatol Surg. 2019 Nov;45(11):1435-1436. [PubMed: 30640778]

11.

Griffiths CE. The clinical identification and quantification of photodamage. Br J Dermatol. 1992 Sep;127 Suppl 41:37-42. [PubMed: 1390185]

12.

Lawrence N. New and emerging treatments for photoaging. Dermatol Clin. 2000 Jan;18(1):99-112. [PubMed: 10626116]

13.

Demetriou C. Reversing precancerous actinic damage by mixing wavelengths (1064 nm, 532 nm). J Cosmet Laser Ther. 2011 Jun;13(3):113-9. [PubMed: 21609213]

14.

Siperstein R, Wikramanayake TC. Intense Pulsed Light as a Treatment for Senile Purpura: A Pilot Study. Lasers Surg Med. 2021 Sep;53(7):926-934. [PubMed: 33615512]

15.

Kimak A, Żebrowska A. Therapeutic Approach in Pigmented Purpuric Dermatoses-A Scoping Review. Int J Mol Sci. 2024 Feb 24;25(5) [PMC free article: PMC10932383] [PubMed: 38473891]

16.

Dehghani A, Seddigh MA, Jafarzadeh A, Behrangi E, Lotfi S, Goodarzi A. A systematic review of the safety and effectiveness of laser and light therapies for the treatment of pigmented purpuric dermatoses. Lasers Med Sci. 2025 Oct 01;40(1):401. [PubMed: 41032121]

17.

Chambers CJ, Liu H, White CR, White KP, Sharon VR. Eruptive purpuric papules on the arms; a case of chemotherapy-induced inflammation of actinic keratoses and review of the literature. Dermatol Online J. 2014 Jan 15;20(1):21246. [PubMed: 24456949]

18.

Lipozenčić J, Bukvić Mokos Z. Dermatologic lasers in the treatment of aging skin. Acta Dermatovenerol Croat. 2010;18(3):176-80. [PubMed: 20887699]

Disclosure: Hasnain Syed declares no relevant financial relationships with ineligible companies.

Disclosure: Sadia Masood declares no relevant financial relationships with ineligible companies.